Silence Therapeutics plc (LON:SLN) had its target price upped by research analysts at Canaccord Genuity from GBX 233 ($3.04) to GBX 249 ($3.25) in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s price objective indicates a potential upside of 111.46% from the stock’s current price.

Silence Therapeutics plc (LON:SLN) opened at 117.75 on Tuesday. Silence Therapeutics plc has a 52 week low of GBX 96.62 and a 52 week high of GBX 259.75. The firm’s market cap is GBX 82.19 million. The company has a 50-day moving average of GBX 113.68 and a 200-day moving average of GBX 116.45.

Silence Therapeutics plc Company Profile

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.

Receive News & Stock Ratings for Silence Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics plc and related stocks with our FREE daily email newsletter.